Botulinum Toxin Treatment of Movement Disorders

被引:32
|
作者
Safarpour, Yasaman [1 ]
Jabbari, Bahman [2 ]
机构
[1] Univ Calif Irvine, Dept Med, Div Nephrol, Irvine, CA 92717 USA
[2] Yale Univ, Sch Med, Dept Neurol, Div Movement Disorders, 31 Silver Pine Dr, Newport Coast, CA 92657 USA
关键词
Botulinum toxin; Movement disorders; Cervical dystonia; Dystonia; Blepharosapasm; Hemifacial spasm; Tremor; BENIGN ESSENTIAL BLEPHAROSPASM; QUALITY-OF-LIFE; INCOBOTULINUMTOXINA NT 201; DYSTONIA PATIENT REGISTRY; PLACEBO-CONTROLLED TRIAL; LONG-TERM EFFICACY; DOUBLE-BLIND; CERVICAL DYSTONIA; HEMIFACIAL SPASM; FACIAL MYOKYMIA;
D O I
10.1007/s11940-018-0488-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Botulinum neurotoxins (BoNTs) are now among the most widely used therapeutic agents in clinical medicine with indications applied to the fields of movement disorders, pain disorders, and autonomic dysfunction. In this literature review, the efficacy and utility of BoNTs in the field of movement disorders are assessed using the criteria of the Guideline Development Subcommittee of the American Academy of Neurology. The literature supports a level A efficacy (established) for BoNT therapy in cervical dystonia and a level B efficacy (probably effective) for blepharospasm, hemifacial spasm, laryngeal dystonia (spasmodic dysphonia), task-specific dystonias, essential tremor, and Parkinson rest tremor. It is the view of movement disorder experts, however, that despite the level B efficacy, BoNTs should be considered treatment of first choice for blepharospasm, hemifacial spasm, laryngeal, and task-specific dystonias. The emerging data on motor and vocal tics of Tourette syndrome and oromandibular dystonias are encouraging but the current level of efficacy is U (undetermined) due to lack of published high-quality studies.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Time to onset and duration of botulinum toxin efficacy in movement disorders
    Claudia Ledda
    Carlo Alberto Artusi
    Antonella Tribolo
    Domiziana Rinaldi
    Gabriele Imbalzano
    Leonardo Lopiano
    Maurizio Zibetti
    Journal of Neurology, 2022, 269 : 3706 - 3712
  • [42] Treatment of laryngeal movement disorders with botulinum toxins
    Schwemmle, C.
    Ptok, M.
    HNO, 2007, 55 (05) : 399 - 402
  • [43] Botulinum Toxin in Peripherally-Induced Movement Disorders - A Multidisciplinary Approach
    Peresa, Rui
    Lopes, Ana Sofia
    Costa, Cristina
    TOXICON, 2024, 237 : 68 - 68
  • [44] Clinical applications of botulinum toxin type B (BotB) in movement disorders
    Molho, ES
    Factor, SA
    MOVEMENT DISORDERS, 2002, 17 : S280 - S280
  • [45] Long-term efficacy of botulinum toxin in facial movement disorders
    Badarny, S.
    Ibrahim, R.
    Susel, Z.
    Zaina, A.
    Nasar, R.
    Badarny, Y.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 635 - 635
  • [46] Development of a patient knowledge questionnaire for botulinum toxin use in movement disorders
    Schoffer, KL
    O'Sullivan, JD
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S328 - S329
  • [47] BOTULINUM TOXIN TREATMENT OF SUPRANUCLEAR OCULAR MOTILITY DISORDERS
    NEWMAN, NJ
    LAMBERT, SR
    NEUROLOGY, 1992, 42 (07) : 1391 - 1393
  • [48] The emerging role of botulinum toxin in the treatment of temporomandibular disorders
    Song, P. C.
    Schwartz, J.
    Blitzer, A.
    ORAL DISEASES, 2007, 13 (03) : 253 - 260
  • [49] Botulinum toxin A: Analgesic treatment for temporomandibular joint disorders
    Denglehem, C.
    Maes, J. -M.
    Raoul, G.
    Ferri, J.
    REVUE DE STOMATOLOGIE DE CHIRURGIE MAXILLO-FACIALE ET DE CHIRURGIE ORALE, 2012, 113 (01) : 27 - 31
  • [50] The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders
    María T. Gómez-Caravaca
    María T. Cáceres-Redondo
    Ismael Huertas-Fernández
    Laura Vargas-González
    Fátima Carrillo
    Manuel Carballo
    Pablo Mir
    Neurological Sciences, 2015, 36 : 275 - 279